Collectively, these insights into molecular mechanisms suggest that combined treatments targeting NUPs could offer effective strategies to trigger p53-, p63-, and p73-mediated cellular responses to oncogenic stress, thereby combating HCC and improving patient outcomes. The gene discussed is TP53; the disease is hepatocellular carcinoma.